Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
VNDA — Vanda Pharmaceuticals Inc.
NASDAQ
FULL STOCK PAGE →

Q2 2026 Earnings Call Summary

AUG 5, 2026
REVENUE
$50.5M -2.3%
NET MARGIN
-123.7% -29.8 PTS
EPS
-$1.04 -26.8%
FREE CASH FLOW
-$81.7M -62.0%

No summary has been written for this call yet.